PMID-sentid Pub_year Sent_text comp_official_name comp_offsetprotein_name organism prot_offset 21543973-0 2011 Levodopa induces synthesis of nerve growth factor and growth hormone in patients with Parkinson disease. Levodopa 0-8 growth hormone 1 Homo sapiens 54-68 21543973-4 2011 Levodopa may experimentally exert supportive effects on nerve growth factor synthesis and on growth hormone production, a hormonal compound with regenerative potential. Levodopa 0-8 growth hormone 1 Homo sapiens 93-107 21543973-5 2011 OBJECTIVE: The objective of this study was to investigate the effects of soluble 250-mg levodopa/benserazide administration on plasma occurrence of levodopa, nerve growth factor, and growth hormone in patients with Parkinson disease over an interval of 60 minutes. Levodopa 88-96 growth hormone 1 Homo sapiens 183-197 21543973-6 2011 RESULTS: Levodopa moderately increased bioavailability of nerve growth factor and growth hormone combined with the rise of levodopa. Levodopa 9-17 growth hormone 1 Homo sapiens 82-96 21543973-8 2011 CONCLUSIONS: Axonal degeneration may not be due to levodopa itself, as levodopa supports production of nerve growth factor and of growth hormone. Levodopa 71-79 growth hormone 1 Homo sapiens 130-144 19570739-3 2009 Children in the GHD-1 subgroup (n=33) had low GH values (<10 microg/L) after clonidine and levo-dopa while those in the GHD-2 subgroup (n=32) had normal GH values after pharmacologic provocation but low 24-hour GH secretory rates compared to 187 Normal Statured (NS) children. Levodopa 94-103 growth hormone 1 Homo sapiens 46-48 19570739-3 2009 Children in the GHD-1 subgroup (n=33) had low GH values (<10 microg/L) after clonidine and levo-dopa while those in the GHD-2 subgroup (n=32) had normal GH values after pharmacologic provocation but low 24-hour GH secretory rates compared to 187 Normal Statured (NS) children. Levodopa 94-103 growth hormone 1 Homo sapiens 46-48 17590511-0 2007 Endurance exercise modulates levodopa induced growth hormone release in patients with Parkinson"s disease. Levodopa 29-37 growth hormone 1 Homo sapiens 46-60 17590511-1 2007 Acute levodopa (LD) application and exercise release human growth hormone (GH). Levodopa 6-14 growth hormone 1 Homo sapiens 59-73 17590511-1 2007 Acute levodopa (LD) application and exercise release human growth hormone (GH). Levodopa 16-18 growth hormone 1 Homo sapiens 59-73 15950665-1 2005 Women of normal weight with polycystic ovary syndrome (PCOS) and hyperinsulinemia presented high growth hormone (GH) levels in response to the l-dopa test, suggesting that the action of GH and insulin-like growth factor-1 (IGF-1) might be responsible for the elevation in LH and the consequent hyperandrogenic anovulation observed in normal weight women with PCOS. Levodopa 143-149 growth hormone 1 Homo sapiens 97-111 17263675-8 2007 All growth hormone (GH) parameters measured and calculated were significantly (p < 0.05) lower in TBI group than in controls after L-DOPA stimulation. Levodopa 134-140 growth hormone 1 Homo sapiens 4-18 17263675-8 2007 All growth hormone (GH) parameters measured and calculated were significantly (p < 0.05) lower in TBI group than in controls after L-DOPA stimulation. Levodopa 134-140 growth hormone 1 Homo sapiens 20-22 15950665-1 2005 Women of normal weight with polycystic ovary syndrome (PCOS) and hyperinsulinemia presented high growth hormone (GH) levels in response to the l-dopa test, suggesting that the action of GH and insulin-like growth factor-1 (IGF-1) might be responsible for the elevation in LH and the consequent hyperandrogenic anovulation observed in normal weight women with PCOS. Levodopa 143-149 growth hormone 1 Homo sapiens 113-115 15950665-1 2005 Women of normal weight with polycystic ovary syndrome (PCOS) and hyperinsulinemia presented high growth hormone (GH) levels in response to the l-dopa test, suggesting that the action of GH and insulin-like growth factor-1 (IGF-1) might be responsible for the elevation in LH and the consequent hyperandrogenic anovulation observed in normal weight women with PCOS. Levodopa 143-149 growth hormone 1 Homo sapiens 186-188 15283001-10 2004 Following only the nighttime administration of L-dopa, RLS patients manifested a more pronounced inhibition of prolactin release and an increase in growth hormone secretion. Levodopa 47-53 growth hormone 1 Homo sapiens 148-162 14644812-10 2003 Many women with polycystic ovary syndrome (PCOS) have an impaired GH response to stimulation with Levo-Dopa and GH releasing hormone (GHRH). Levodopa 98-107 growth hormone 1 Homo sapiens 66-68 14751427-0 2004 Effects of antidepressant treatment on thyrotropin-releasing hormone stimulation, growth hormone response to L-DOPA, and dexamethasone suppression tests in major depressive patients. Levodopa 109-115 growth hormone 1 Homo sapiens 82-96 14751427-2 2004 TSH responses to TRH showed a tendency to increase from pre- to posttreatment period, while TRH-induced PRL and L-DOPA-induced GH responses did not change with treatment in depressed patients who responded to the treatment. Levodopa 112-118 growth hormone 1 Homo sapiens 127-129 14751427-4 2004 No interconnections were found among the responses in DST, TRH stimulation test and L-DOPA-induced GH test in the patients. Levodopa 84-90 growth hormone 1 Homo sapiens 99-101 15221500-5 2004 GH stimulation tests were performed after the ingestion of 500 mg of L-dopa. Levodopa 69-75 growth hormone 1 Homo sapiens 0-2 15198291-6 2004 GH levels were measured in patients with SCD with and without growth failure using arginine and L-Dopa as provocative stimulation tests. Levodopa 96-102 growth hormone 1 Homo sapiens 0-2 9583205-4 1998 Growth hormone stimulation tests were done with L-dopa and clonidine before or during acidosis therapy and after the correction of metabolic acidosis. Levodopa 48-54 growth hormone 1 Homo sapiens 0-14 10830457-0 2000 Simultaneous stimulation of growth hormone, adrenocorticotropin and cortisol with L-dopa/L-carbidopa and propranolol in children of short stature. Levodopa 82-88 growth hormone 1 Homo sapiens 28-42 10830457-9 2000 We conclude that the administration of L-dopa/L-carbidopa and propranolol is useful for the simultaneous evaluation of growth hormone, cortisol and ACTH secretion in children of short stature. Levodopa 39-45 growth hormone 1 Homo sapiens 119-133 10352397-11 1999 GH response to L-dopa stimulation was blunted in all subjects and it was increased after treatment in both groups. Levodopa 15-21 growth hormone 1 Homo sapiens 0-2 9929973-12 1999 When group I was subdivided into group A (with the A1 allele) and group B (with only the A2 allele), group A had a significantly lower peak GH response to the l-dopa test, lower levels of IGF-I, and retarded bone maturation. Levodopa 159-165 growth hormone 1 Homo sapiens 140-142 10731533-6 2000 A GH stimulation test with oral L-dopa was arranged for controls and for patients with PCOS before and again 6 months later after OWR. Levodopa 32-38 growth hormone 1 Homo sapiens 2-4 10731533-9 2000 The OWR in patients with PCOS obviously reduced their androstenedione and testosterone levels and insulin-glucose ratios, and increased the GH and GH-IGF-1 responses to L-dopa. Levodopa 169-175 growth hormone 1 Homo sapiens 140-142 10584673-6 1999 In conclusion, in patients with MSA, the GHRH and GH responses to L-dopa were preserved and were similar to responses in age-matched control subjects. Levodopa 66-72 growth hormone 1 Homo sapiens 41-43 9224438-6 1997 RESULTS: Plasma IGF-I concentrations and the GH responses to sumatriptan, sodium valproate and L-Dopa were significantly lower in older than in younger women. Levodopa 95-101 growth hormone 1 Homo sapiens 45-47 9639745-0 1997 [Responses of growth hormone and prolactin to L-Dopa in women with polycystic ovarian syndrome]. Levodopa 46-52 growth hormone 1 Homo sapiens 14-28 9255200-4 1997 Growth hormone reserve was assessed by at least two stimulation tests (clonidine, L-dopa, growth hormone-releasing hormone). Levodopa 82-88 growth hormone 1 Homo sapiens 0-14 7920871-0 1994 Reduced growth hormone response to L-dopa and pyridostigmine in obesity. Levodopa 35-41 growth hormone 1 Homo sapiens 8-22 9178029-8 1997 We conclude that 1) the elevated IR-GHRH in the cord blood plasma originates from the fetus and may have a primary role in enhancing secretion of GH which promotes growth in early human life, and 2) the participations of GHRH in the mechanisms of GH secretion seen after administrations of L-dopa, L-arginine and somatostatin are different. Levodopa 290-296 growth hormone 1 Homo sapiens 36-38 9004111-5 1996 The delta serum GH during levodopa was 5.7 +/- 6.3 ng ml-1 in DS and 13.1 +/- 9.8 ng ml-1 in controls. Levodopa 26-34 growth hormone 1 Homo sapiens 16-18 9004111-11 1996 These results indicate that levodopa and clonidine (drugs stimulating hypothalamic GHRH release and secondary pituitary GH release in normal individuals) do not stimulate GH release in DS. Levodopa 28-36 growth hormone 1 Homo sapiens 83-85 8836934-6 1996 As expected, LD/carbidopa increased the concentration of GH and decreased that of PRL. Levodopa 13-15 growth hormone 1 Homo sapiens 57-59 8747120-6 1995 In response to L-dopa and arginine hydrochloride stimulation, serum GH rose to above 7 mg/ml in all patients. Levodopa 15-21 growth hormone 1 Homo sapiens 68-70 7603406-3 1995 Growth hormone (GH) reserve was assessed by two different provocative stimuli (Clonidine and L-Dopa). Levodopa 93-99 growth hormone 1 Homo sapiens 0-14 7603406-3 1995 Growth hormone (GH) reserve was assessed by two different provocative stimuli (Clonidine and L-Dopa). Levodopa 93-99 growth hormone 1 Homo sapiens 16-18 8867520-5 1996 At the beginning of the study, basal hormonal levels were within normal limits, and levodopa administration induced a significant suppression in PRL and TSH levels (both p < 0.01)) and a significant increase in GH (p < 0.01). Levodopa 84-92 growth hormone 1 Homo sapiens 211-213 8867520-10 1996 The dopaminergic effects of levodopa on TSH, GH, and IGF-I secretion were unchanged by terguride treatment. Levodopa 28-36 growth hormone 1 Homo sapiens 45-47 7993663-3 1994 Two patients with propionic acidemia had decreased growth hormone secretion in response to provocative stimuli (intravenous L-arginine and oral levodopa or clonidine); the remaining subjects had sufficient growth hormone secretion. Levodopa 144-152 growth hormone 1 Homo sapiens 51-65 7920871-5 1994 Growth hormone responses and GH area under the response curve (AUC) to L-dopa were significantly lower in obese subjects than those in controls. Levodopa 71-77 growth hormone 1 Homo sapiens 29-31 7920871-6 1994 Pyridostigmine significantly enhanced the GH response to L-dopa in both obese and control subjects. Levodopa 57-63 growth hormone 1 Homo sapiens 42-44 7920871-7 1994 However, enhanced GH responses in obese subjects were attenuated biologically and lower than those in controls with L-dopa only. Levodopa 116-122 growth hormone 1 Homo sapiens 18-20 8243704-0 1993 Diminished growth hormone responses to L-dopa in polycystic ovarian disease. Levodopa 39-45 growth hormone 1 Homo sapiens 11-25 9160587-0 1994 Growth hormone response to clonidine and L-dopa in normal volunteers. Levodopa 41-47 growth hormone 1 Homo sapiens 0-14 8513959-0 1993 Growth hormone response to L-dopa and pyridostigmine in women with polycystic ovarian syndrome. Levodopa 27-33 growth hormone 1 Homo sapiens 0-14 8210606-0 1993 Growth hormone response after administration of L-dopa, clonidine, and growth hormone releasing hormone in children with Down syndrome. Levodopa 48-54 growth hormone 1 Homo sapiens 0-14 8210606-1 1993 We studied the response of growth hormone secretion after the administration of L-dopa, clonidine, and growth hormone releasing hormone in eight growth-retarded children with Down syndrome aged 1 to 6.5 years. Levodopa 80-86 growth hormone 1 Homo sapiens 27-41 8406335-7 1993 This suggests a specific but as yet undetermined effect of L-dopa on urinary GH secretion. Levodopa 59-65 growth hormone 1 Homo sapiens 77-79 8262472-4 1993 GH secretion in response to pharmacological stimuli (insulin, arginine and/or L-Dopa) was evaluated when growth failure occurred. Levodopa 78-84 growth hormone 1 Homo sapiens 0-2 1518496-1 1992 In this study, on the basis of the inhibiting action of l-dopa administration on prolactin (PRL) secretion, we evaluated in a number of short children the levels of PRL during the provocative stimuli test with l-dopa in order to identify an index able to give reliability to the test and to investigate whether some differences may exist among the subjects showing a different response in growth hormone (GH) secretion to l-dopa. Levodopa 56-62 growth hormone 1 Homo sapiens 389-403 1595643-4 1992 In both controls and treated patients, TRH did not influence GH secretion, whereas L-dopa significantly increased GH levels. Levodopa 83-89 growth hormone 1 Homo sapiens 114-116 1595643-6 1992 Because L-dopa would stimulate hypothalamic GH-releasing hormone (GHRH) secretion, four untreated patients, unresponsive to L-dopa, received GHRH, and GH levels rose markedly. Levodopa 8-14 growth hormone 1 Homo sapiens 44-46 1346143-5 1992 Our data showed a significant increase (P less than 0.001) in GH, GHRH, and SRIH levels (peak vs. basal values) in response to L-dopa administration in all groups. Levodopa 127-133 growth hormone 1 Homo sapiens 62-64 1533556-4 1992 GH was evaluated by levodopa (125 mg up to 15 kg, and 250 mg between 15-30 kg), clonidine (0.15 mg m-2) stimulation tests and hGH secretory patterns by the integrated 24 h. GH concentration (IC-GH) using a constant withdrawal pump with continuous blood collection every 30 min. Levodopa 20-28 growth hormone 1 Homo sapiens 0-2 1533556-6 1992 Peak serum GH after levodopa and clonidine was found to be below 10 ng ml-1 for both stimulatory tests in seven out of the 20 children studied. Levodopa 20-28 growth hormone 1 Homo sapiens 11-13 1961117-0 1991 Age-related decrease in plasma growth hormone: response to growth hormone-releasing hormone, arginine, and L-dopa in obesity. Levodopa 107-113 growth hormone 1 Homo sapiens 31-45 1345575-4 1992 TRH 0.2 mg iv blunted GH response to L-dopa 0.5 g p.o. Levodopa 37-43 growth hormone 1 Homo sapiens 22-24 1961117-5 1991 The mean peak levels of plasma GH in response to GRH, arginine, and L-dopa in obese subjects were 11.3 +/- 2.1, 21.9 +/- 4.4, and 5.2 +/- 0.3 ng/mL in adolescents, 8.2 +/- 1.6, 9.1 +/- 1.5, and 3.1 +/- 0.6 ng/mL in those in their 20s, and 4.5 +/- 0.4, 7.3 +/- 1.4, and 2.8 +/- 0.3 ng/mL in those 30 years or older, respectively, showing a significant decrease in peak GH level with advancing age (P less than .05 to P less than .01). Levodopa 68-74 growth hormone 1 Homo sapiens 31-33 1674920-4 1991 Br or L-Dopa was considered to be effective when serum GH or PRL levels were suppressed more than 50% of the basal value. Levodopa 6-12 growth hormone 1 Homo sapiens 55-57 1831841-3 1991 Before treatment, peak serum growth hormone concentrations were less than 10 micrograms/L after levodopa and clonidine stimulation tests in five patients, after clonidine in three patients, and after levodopa in three patients. Levodopa 96-104 growth hormone 1 Homo sapiens 29-43 1782731-11 1991 Standardized exercise is as effective as L-DOPA/P as a stimulation test for growth hormone response in very short children with abnormal growth velocities. Levodopa 41-47 growth hormone 1 Homo sapiens 76-90 1674920-9 1991 Suppression of serum GH level by L-Dopa was also observed in the Ss group. Levodopa 33-39 growth hormone 1 Homo sapiens 21-23 1709847-6 1991 Levodopa (L-dopa) [125 to 500mg orally], the physiological precursor of the catecholamines, administered either alone or in combination with carbidopa (50mg orally), to prevent its peripheral decarboxylation to dopamine, and/or the beta-adrenoceptor antagonist propranolol (0.75 mg/kg orally), and the alpha 2-adrenoceptor agonist clonidine (0.15 mg/m2 orally), are a fairly reliable stimulus of GH release. Levodopa 0-8 growth hormone 1 Homo sapiens 396-398 1843006-2 1991 The secretion of GH was studied by means of insulin (ITT), glucose (GTT), lysine-vasopressin (LVP), and L-Dopa administrations. Levodopa 104-110 growth hormone 1 Homo sapiens 17-19 1986445-5 1991 Impaired growth hormone (GH) secretion was present in 6 patients after insulin-induced hypoglycaemia and L-dopa administration. Levodopa 105-111 growth hormone 1 Homo sapiens 9-23 1986445-5 1991 Impaired growth hormone (GH) secretion was present in 6 patients after insulin-induced hypoglycaemia and L-dopa administration. Levodopa 105-111 growth hormone 1 Homo sapiens 25-27 1843006-5 1991 Contrarily, after L-Dopa administration, GH elevations were normal in the two younger and absent in the oldest case. Levodopa 18-24 growth hormone 1 Homo sapiens 41-43 2118219-0 1990 Very-low-calorie diet-induced weight reduction reverses impaired growth hormone secretion response to growth hormone-releasing hormone, arginine, and L-dopa in obesity. Levodopa 150-156 growth hormone 1 Homo sapiens 65-79 2279968-0 1990 Growth hormone response to L-dopa and clonidine in autistic children. Levodopa 27-33 growth hormone 1 Homo sapiens 0-14 2279968-8 1990 In the autistic subjects, the L-Dopa-stimulated growth hormone peak was delayed and the clonidine growth hormone peak was premature. Levodopa 30-36 growth hormone 1 Homo sapiens 48-62 2270318-1 1990 We sought to clarify the mechanisms of growth hormone (GH) secretion induced by insulin hypoglycemia, L-dopa, and arginine in man. Levodopa 102-108 growth hormone 1 Homo sapiens 39-53 2084146-10 1990 Challenge with either L-dopa or clonidine produced a peak GH response of 2.3 ng/ml (normals = greater than 7 ng/ml). Levodopa 22-28 growth hormone 1 Homo sapiens 58-60 2118219-3 1990 GH response to GRH, arginine, and L-dopa in obese subjects was markedly impaired before weight reduction, whereas significantly increased responses were noted after weight reduction (P less than .01). Levodopa 34-40 growth hormone 1 Homo sapiens 0-2 2118219-4 1990 Impaired integrated GH response to GRH, arginine, and L-dopa in obese subjects was significantly restored after weight reduction (P less than .01). Levodopa 54-60 growth hormone 1 Homo sapiens 20-22 2318945-0 1990 Blindness impairs plasma growth hormone response to L-dopa but not to arginine. Levodopa 52-58 growth hormone 1 Homo sapiens 25-39 1697660-4 1990 In 8 children, PD and L-dopa when administered alone induced an equivalent GH rise (area under the response curve, mean +/- SEM: 241.4 +/- 31.1 vs. 202.9 +/- 38.6 micrograms/l/h) while their coadministration had an additive effect (435.4 +/- 41.4 micrograms/l/h; p less than 0.02 vs. PD and L-dopa alone). Levodopa 22-28 growth hormone 1 Homo sapiens 75-77 1697660-7 1990 These data show that the enhancement of the cholinergic activity by PD increases the L-dopa-induced GH release but fails to modify both Arg- and GAL-induced GH release in short children. Levodopa 85-91 growth hormone 1 Homo sapiens 100-102 876212-0 1977 [Stimulation of the secretion of somatotropin by administration of Nacom (L-dopa and L-carbidopa) in ambulatory patients with retarded growth]. Levodopa 74-80 growth hormone 1 Homo sapiens 33-45 3243205-0 1988 Diminished growth hormone secretion in blind males after L-dopa stimulation. Levodopa 57-63 growth hormone 1 Homo sapiens 11-25 2669475-4 1989 GH levels did not increase after TRH or LHRH administration but decreased after L-Dopa and glucose. Levodopa 80-86 growth hormone 1 Homo sapiens 0-2 2497615-0 1989 Influence of estrogen administration on growth hormone response to GHRH and L-Dopa in patients with Turner"s syndrome. Levodopa 76-82 growth hormone 1 Homo sapiens 40-54 2645703-7 1989 Of 53 patients, 23 were able to discontinue prednisone and be maintained on monodrug cyclosporine therapy, and 21 of the 53 patients had growth hormone measured using L-dopa stimulation. Levodopa 167-173 growth hormone 1 Homo sapiens 137-151 2645703-11 1989 Based on these data we suggest that (1) discontinuation of even very small doses of prednisone may be essential for normalizing growth hormone response to L-dopa and (2) further studies are needed to exploit the growth stimulation effect of recombinant growth hormone in transplanted children. Levodopa 155-161 growth hormone 1 Homo sapiens 128-142 2495961-4 1989 The treatment significantly increased growth hormone (GH) response to L-dopa administration (P less than 0.025) as well as sleep GH secretion (P less than 0.025). Levodopa 70-76 growth hormone 1 Homo sapiens 38-52 34956087-8 2021 The peak value of growth hormone was 10.26 ng/ml in the levodopa provocation test. Levodopa 56-64 growth hormone 1 Homo sapiens 18-32 3243205-1 1988 Growth hormone secretion after L-dopa administration (1000 mg p.o.) Levodopa 31-37 growth hormone 1 Homo sapiens 0-14 3243205-3 1988 The average increment of plasma growth hormone after L-dopa stimulation in the blind was below the criterion for a positive response (less than 5 ng ml-1). Levodopa 53-59 growth hormone 1 Homo sapiens 32-46 3243205-5 1988 After L-dopa stimulation there was a significantly diminished growth hormone response in the young adult blind compared to control volunteers. Levodopa 6-12 growth hormone 1 Homo sapiens 62-76 3243342-1 1988 Basal and L-dopa-stimulated secretion of growth hormone (GH) was investigated in 10 patients with beta-thalassaemia major. Levodopa 10-16 growth hormone 1 Homo sapiens 41-55 3243342-1 1988 Basal and L-dopa-stimulated secretion of growth hormone (GH) was investigated in 10 patients with beta-thalassaemia major. Levodopa 10-16 growth hormone 1 Homo sapiens 57-59 3243342-6 1988 In contrast, the pituitary responsiveness to L-dopa, expressed as the relative maximum response for GH (GH delta %), was significantly higher in the latter two groups (8.5-fold, p less than 0.05, and 10.9-fold, p less than 0.02, respectively). Levodopa 45-51 growth hormone 1 Homo sapiens 100-102 3243342-6 1988 In contrast, the pituitary responsiveness to L-dopa, expressed as the relative maximum response for GH (GH delta %), was significantly higher in the latter two groups (8.5-fold, p less than 0.05, and 10.9-fold, p less than 0.02, respectively). Levodopa 45-51 growth hormone 1 Homo sapiens 104-106 3177326-4 1988 Growth hormone release was evaluated by arginine and levodopa tests after the end of treatment. Levodopa 53-61 growth hormone 1 Homo sapiens 0-14 3141449-7 1988 These findings suggest that 1) the impaired GH release after GHRH, arginine, and L-dopa administration in MD patients is not due to somatotroph deficiency, since the GH response to hypoglycemia is well preserved; and 2) insulin-induced hypoglycemia may stimulate GH release at least in part via inhibition of somatostatin release. Levodopa 81-87 growth hormone 1 Homo sapiens 44-46 3141449-1 1988 Plasma GH responses to human GHRH, arginine, L-dopa, and insulin-induced hypoglycemia were determined in seven myotonic dystrophy (MD) patients. Levodopa 45-51 growth hormone 1 Homo sapiens 7-9 3141449-5 1988 The plasma GH responses to a 30-min iv infusion of arginine (0.5 g/kg BW) and oral ingestion of L-dopa (0.5 g) were attenuated to a similar extent, whereas insulin-induced hypoglycemia caused a significant increase in plasma GH in all seven MD patients [mean peak, 17.4 +/- 4.1 (+/- SE) microgram/L]. Levodopa 96-102 growth hormone 1 Homo sapiens 11-13 3141449-5 1988 The plasma GH responses to a 30-min iv infusion of arginine (0.5 g/kg BW) and oral ingestion of L-dopa (0.5 g) were attenuated to a similar extent, whereas insulin-induced hypoglycemia caused a significant increase in plasma GH in all seven MD patients [mean peak, 17.4 +/- 4.1 (+/- SE) microgram/L]. Levodopa 96-102 growth hormone 1 Homo sapiens 225-227 3138280-0 1988 Variable plasma growth hormone (GH)-releasing hormone and GH responses to clonidine, L-dopa, and insulin in normal men. Levodopa 85-91 growth hormone 1 Homo sapiens 32-34 3138280-0 1988 Variable plasma growth hormone (GH)-releasing hormone and GH responses to clonidine, L-dopa, and insulin in normal men. Levodopa 85-91 growth hormone 1 Homo sapiens 58-60 3138280-7 1988 L-Dopa increased plasma ir-GHRH at 60 min (P less than 0.05) and GH at 60-120 min (P less than 0.05). Levodopa 0-6 growth hormone 1 Homo sapiens 27-29 3145820-0 1988 Growth hormone (GH) responses to arginine and L-dopa alone and after GHRH pretreatment. Levodopa 46-52 growth hormone 1 Homo sapiens 0-14 3145820-8 1988 L-dopa alone induced a rise in GH levels maximal at 90 min (17.6 +/- 7.4 mU/l, mean +/- SEM) but this rise was abolished by pretreatment with GHRH. Levodopa 0-6 growth hormone 1 Homo sapiens 31-33 3170408-9 1988 After treatment with met-hGH, five of seven subjects had a suppressed GH response to stimulation from either L-dopa/arginine or submaximal exercise. Levodopa 109-116 growth hormone 1 Homo sapiens 26-28 3145820-0 1988 Growth hormone (GH) responses to arginine and L-dopa alone and after GHRH pretreatment. Levodopa 46-52 growth hormone 1 Homo sapiens 16-18 3145820-1 1988 In order to investigate the mechanisms by which arginine and L-dopa cause GH release in humans we measured the GH response to GHRH 1-44 (200 micrograms i.v. Levodopa 61-67 growth hormone 1 Homo sapiens 74-76 2897907-1 1988 This article summarizes the existing neuroendocrine literature and reports the growth hormone response to stimulation with L-dopa and clonidine in male children and adolescents with attention deficit hyperactivity disorder. Levodopa 123-129 growth hormone 1 Homo sapiens 79-93 3380074-1 1988 This article summarizes the existing neuroendocrine literature and reports the growth hormone response to stimulation with L-dopa and clonidine in male children and adolescents with attention deficit hyperactivity disorder. Levodopa 123-129 growth hormone 1 Homo sapiens 79-93 3123283-2 1987 In normal subjects, the plasma GHRH concentration was increased from the basal value of 9.8 +/- 1.4 pg/ml (mean +/- SE) to 34.8 +/- 3.1 pg/ml at 30 approximately 90 min after oral administration of 500 mg L-dopa, followed by a rise of GH release (plasma GH level from less than 1 ng/ml to 21.7 +/- 4.7 ng/ml) in most cases, indicating that L-dopa stimulates GH secretion via hypothalamic GHRH. Levodopa 340-346 growth hormone 1 Homo sapiens 31-33 3118729-1 1987 The growth hormone (GH) responses to (A) GRF 1-44, 1 microgram/kg i.v., (B) L-dopa and either arginine, insulin, or glucagon, and (C) exercise were evaluated in 10 children (3 girls, 7 boys; ages 10 years to 15 years, 8 months), 2-10.75 years following cranial irradiation for medulloblastoma (8 patients), pineoblastoma (1 patient), and a fourth ventricular ependymoma (1 patient). Levodopa 76-82 growth hormone 1 Homo sapiens 4-18 3118729-1 1987 The growth hormone (GH) responses to (A) GRF 1-44, 1 microgram/kg i.v., (B) L-dopa and either arginine, insulin, or glucagon, and (C) exercise were evaluated in 10 children (3 girls, 7 boys; ages 10 years to 15 years, 8 months), 2-10.75 years following cranial irradiation for medulloblastoma (8 patients), pineoblastoma (1 patient), and a fourth ventricular ependymoma (1 patient). Levodopa 76-82 growth hormone 1 Homo sapiens 20-22 3123283-1 1987 The responses of plasma growth hormone-releasing hormone (GHRH) and growth hormone (GH) to oral administration of L-dopa were studied in normal subjects and patients with various endocrine and metabolic diseases to clarify the pathophysiological role of the GHRH-GH axis. Levodopa 114-120 growth hormone 1 Homo sapiens 24-38 3123283-1 1987 The responses of plasma growth hormone-releasing hormone (GHRH) and growth hormone (GH) to oral administration of L-dopa were studied in normal subjects and patients with various endocrine and metabolic diseases to clarify the pathophysiological role of the GHRH-GH axis. Levodopa 114-120 growth hormone 1 Homo sapiens 58-60 3123283-2 1987 In normal subjects, the plasma GHRH concentration was increased from the basal value of 9.8 +/- 1.4 pg/ml (mean +/- SE) to 34.8 +/- 3.1 pg/ml at 30 approximately 90 min after oral administration of 500 mg L-dopa, followed by a rise of GH release (plasma GH level from less than 1 ng/ml to 21.7 +/- 4.7 ng/ml) in most cases, indicating that L-dopa stimulates GH secretion via hypothalamic GHRH. Levodopa 205-211 growth hormone 1 Homo sapiens 31-33 3123283-4 1987 In patients with acromegaly, the plasma levels of GHRH remained stationary after the L-dopa administration and did not correlate with plasma GH levels. Levodopa 85-91 growth hormone 1 Homo sapiens 50-52 3123283-5 1987 In subjects with simple obesity, the responses of plasma GHRH (peak 13.2 +/- 1.2 pg/ml) and GH (peak 4.3 +/- 1.7 ng/ml) to L-dopa were significantly lower than those in normal subjects (p less than 0.01). Levodopa 123-129 growth hormone 1 Homo sapiens 57-59 3123283-9 1987 These findings suggest that GH secretion evoked by the L-dopa administration is induced by GHRH released from the hypothalamus, and impairment of GH secretion associated with simple obesity, primary hypothyroidism, or NIDDM may be in part attributed to insufficiency of GHRH release from the hypothalamus, and indicate that L-dopa test is clinically useful for evaluating the ability of intrinsic GHRH release in such diseased states. Levodopa 55-61 growth hormone 1 Homo sapiens 28-30 3123283-9 1987 These findings suggest that GH secretion evoked by the L-dopa administration is induced by GHRH released from the hypothalamus, and impairment of GH secretion associated with simple obesity, primary hypothyroidism, or NIDDM may be in part attributed to insufficiency of GHRH release from the hypothalamus, and indicate that L-dopa test is clinically useful for evaluating the ability of intrinsic GHRH release in such diseased states. Levodopa 324-330 growth hormone 1 Homo sapiens 28-30 6431057-2 1984 After phenytoin treatment, growth hormone response to levodopa increased. Levodopa 54-62 growth hormone 1 Homo sapiens 27-41 3793848-0 1987 Growth hormone inhibitory and stimulatory actions of L-dopa in patients with acromegaly. Levodopa 53-59 growth hormone 1 Homo sapiens 0-14 2424323-3 1986 Patients were given an overnight dexamethasone suppression test, and the effects of thyrotropin-releasing hormone and L-dopa on plasma growth hormone and prolactin were examined. Levodopa 118-124 growth hormone 1 Homo sapiens 135-149 6499233-0 1984 Inhibitory effect of cimetidine on L-dopa-stimulated growth hormone release in normal man. Levodopa 35-41 growth hormone 1 Homo sapiens 53-67 6431057-0 1984 Phenytoin-induced increase in growth hormone response to levodopa in adult males. Levodopa 57-65 growth hormone 1 Homo sapiens 30-44 6735152-14 1984 Plasma concentrations of GH were reduced by the peripheral administration of NE, which might be expected not to cross the blood-brain-barrier (BBB), alpha 1/alpha 2 agonists clonidine and p-amino clonidine (which does not cross BBB), NE/E precursors L-DOPA and DOPS, and the beta agonist, isoproterenol. Levodopa 250-256 growth hormone 1 Homo sapiens 25-27 6539375-5 1984 Both parents were heterozygous for the hGH-N gene deletion and had a low hGH response to arginine and L-dopa tolerance tests, but had normal basal somatomedin-C levels and normal somatomedin-C generation tests. Levodopa 102-108 growth hormone 1 Homo sapiens 39-44 2887537-7 1987 Loss of dopamine (30-40%) in the hypothalamus of affected patients has been shown in recent studies, and is compatible with the reported abnormalities of growth hormone release in response to L-dopa administration, elevated plasma levels of MSH, and reduced CSF levels of somatostatin and beta-endorphins in these patients. Levodopa 192-198 growth hormone 1 Homo sapiens 154-168 3935892-5 1985 This effect was not potentiated by L-deprenyl, although L-dopa-induced growth hormone secretion was increased after L-deprenyl premedication. Levodopa 56-62 growth hormone 1 Homo sapiens 71-85 3935892-6 1985 There was negative correlation between growth hormone secretion and the increase of plasma homovanillic acid after L-dopa. Levodopa 115-121 growth hormone 1 Homo sapiens 39-53 3997747-0 1985 Plasma growth hormone response to oral l-dopa in infantile autism. Levodopa 39-45 growth hormone 1 Homo sapiens 7-21 3997747-2 1985 The results indicate a high incidence (at least 30%) of blunted plasma growth hormone (GH) responses following oral administration of l-dopa in this sample. Levodopa 134-140 growth hormone 1 Homo sapiens 71-85 3997747-2 1985 The results indicate a high incidence (at least 30%) of blunted plasma growth hormone (GH) responses following oral administration of l-dopa in this sample. Levodopa 134-140 growth hormone 1 Homo sapiens 87-89 6432894-0 1984 The growth hormone responses to L-dopa and TRH in acromegaly. Levodopa 32-38 growth hormone 1 Homo sapiens 4-18 6431057-3 1984 There was a close relationship between growth hormone response to levodopa and plasma phenytoin concentrations. Levodopa 66-74 growth hormone 1 Homo sapiens 39-53 6688812-0 1983 Cholinergic receptor control mechanisms for L-dopa, apomorphine, and clonidine-induced growth hormone secretion in man. Levodopa 44-50 growth hormone 1 Homo sapiens 87-101 6374488-2 1984 Oral administration of L-dopa plus propranolol induced a potent and sustained GH release in the subjects tested (26 +/- 6 ng/ml). Levodopa 23-29 growth hormone 1 Homo sapiens 78-80 6374488-5 1984 completely suppressed the L-dopa-induced GH secretion (2 +/- 09.5 ng/ml). Levodopa 26-32 growth hormone 1 Homo sapiens 41-43 6861440-4 1983 Serum GH did not rise in nonacromegalic subjects, but it fell after 400 mg ibopamine in the L-dopa-sensitive acromegalic patients. Levodopa 92-98 growth hormone 1 Homo sapiens 6-8 6649642-0 1983 [The L-DOPA-propranolol test for the evaluation of reserves in secretory growth hormone]. Levodopa 5-11 growth hormone 1 Homo sapiens 73-87 6634455-0 1983 [Growth hormone secretion in patients with various types of diabetes mellitus and in healthy persons after L-dopa stimulation]. Levodopa 107-113 growth hormone 1 Homo sapiens 1-15 6402812-4 1983 The latter reacted to both the specific L-Dopa test and to the non-specific TRH test with an increase in GH serum concentration. Levodopa 40-46 growth hormone 1 Homo sapiens 105-107 6621850-0 1983 Prolactin and growth hormone response to levodopa in affective illness. Levodopa 41-49 growth hormone 1 Homo sapiens 14-28 6621850-1 1983 Prolactin (PRL) and growth hormone (GH) response to L-Dopa have been studied in 51 affectively ill women (26 unipolar and 25 bipolar) before and after amitriptyline treatment and in 14 normal female controls. Levodopa 52-58 growth hormone 1 Homo sapiens 36-38 6621850-2 1983 There was no difference in GH response to L-dopa in all groups studied except for bipolar postmenopausal women, who showed a blunted GH response to L-Dopa compared to bipolar premenopausal women. Levodopa 148-154 growth hormone 1 Homo sapiens 133-135 6343098-0 1983 Effect of l-dopa on growth hormone, glucose, insulin, and cortisol response in obese subjects. Levodopa 10-16 growth hormone 1 Homo sapiens 20-34 6343098-3 1983 The obese subjects displayed a lack of growth hormone responsiveness to L-dopa and a diminished GH responsiveness to hypoglycemia. Levodopa 72-78 growth hormone 1 Homo sapiens 39-53 7096047-0 1982 Growth hormone response to L-dopa in the thinned obese. Levodopa 27-33 growth hormone 1 Homo sapiens 0-14 6757593-0 1982 [Response of growth hormone (HGH) to L-dopa, L-arginine and their combination in normal individuals]. Levodopa 37-43 growth hormone 1 Homo sapiens 13-27 6749630-2 1982 L-Dopa administration increases insulin binding from 5.18 +/- 0.14% (mean +/- SEM) to 6.18 +/- 0.34% (P less than 0.05) with concomitant increase in basal plasma growth hormone from 1.3 +/- 0.1 ng/ml to 14.4 +/- 4.8 ng/ml (P less than 0.05). Levodopa 0-6 growth hormone 1 Homo sapiens 162-176 7096047-1 1982 The response of plasma growth hormone (GH) to 0.5 g L-dopa was studied in 17 obese nondiabetic subjects and in 6 normal-weight subjects, aged 16 to 46 yr. Levodopa 52-58 growth hormone 1 Homo sapiens 23-37 7334406-2 1981 In subjects on chronic therapy with levodopa and carbidopa (Sinemet), the growth hormone releasing effect of Madopar was blunted. Levodopa 36-44 growth hormone 1 Homo sapiens 74-88 6805079-9 1982 Seven patients with increased GH levels who were challenged with L-dopa showed the typical decrease in GH levels found in this condition; in 5 of these patients, challenged with TRH, GH levels increased. Levodopa 65-71 growth hormone 1 Homo sapiens 30-32 6805079-9 1982 Seven patients with increased GH levels who were challenged with L-dopa showed the typical decrease in GH levels found in this condition; in 5 of these patients, challenged with TRH, GH levels increased. Levodopa 65-71 growth hormone 1 Homo sapiens 103-105 6805079-9 1982 Seven patients with increased GH levels who were challenged with L-dopa showed the typical decrease in GH levels found in this condition; in 5 of these patients, challenged with TRH, GH levels increased. Levodopa 65-71 growth hormone 1 Homo sapiens 103-105 7251816-0 1981 Dopaminergic regulation of growth hormone (GH) secretion in normal man: correlation of L-dopa and dopamine levels with the GH response. Levodopa 87-93 growth hormone 1 Homo sapiens 123-125 6790560-0 1981 Calcium and calcium-antagonistic effects on prolactin and growth hormone responses to thyrotropin-releasing hormone and L-dopa in man. Levodopa 120-126 growth hormone 1 Homo sapiens 58-72 7217982-5 1981 Growth hormone (GH) release in vivo is stimulated by levodopa in normal subjects but inhibited in acromegaly. Levodopa 53-61 growth hormone 1 Homo sapiens 0-14 6790202-3 1981 In this study basal GH plasma levels and their response to TRH and L-DOPA were determined in thirty-nine cirrhotic patients and fifteen controls. Levodopa 67-73 growth hormone 1 Homo sapiens 20-22 7217982-5 1981 Growth hormone (GH) release in vivo is stimulated by levodopa in normal subjects but inhibited in acromegaly. Levodopa 53-61 growth hormone 1 Homo sapiens 16-18 7217982-8 1981 It is suggested that the paradoxical GH response to levodopa in acromegaly can be explained by a dual action of dopamine at hypothalamic and pituitary levels. Levodopa 52-60 growth hormone 1 Homo sapiens 37-39 7217816-0 1981 L-dopa stimulation at growth hormone release in normal subjects and in patients with Sheehan"s syndrome. Levodopa 0-6 growth hormone 1 Homo sapiens 22-36 7288433-0 1981 Lack of an effect of melatonin on the basal and L-dopa stimulated growth hormone secretion in men. Levodopa 48-54 growth hormone 1 Homo sapiens 66-80 6793694-5 1981 Potentiation of L-dopa-induced GH release by L-deprenyl indicates an increased availability of dopamine at the receptor level without a direct agonistic effect by the drug. Levodopa 16-22 growth hormone 1 Homo sapiens 31-33 6781216-3 1980 The pituitary release mechanism for growth hormone was evaluated using the propanolol/L-dopa stimulation test. Levodopa 86-92 growth hormone 1 Homo sapiens 36-50 7357832-4 1980 Whereas L-dopa elicited a growth hormone response of similar magnitude in both groups, clonidine infusion induced a significant increase in serum growth hormone in normotensive, but not in hypertensive, subjects. Levodopa 8-14 growth hormone 1 Homo sapiens 26-40 520175-1 1979 The effect of simultaneous administration of 250 mg L-dopa + 25 mg L-carbidopa (Nacom) and 1 mg propranolol/kg body weight (maximal dose 40 mg propranolol) on growth-hormone secretion was tested in 96 children with growth retardation. Levodopa 52-58 growth hormone 1 Homo sapiens 159-173 7216342-0 1980 Stimulatory effect of levodopa and propranolol upon plasma growth hormone release in children and adolescents. Levodopa 22-30 growth hormone 1 Homo sapiens 59-73 520175-0 1979 [Improvement of growth-hormone stimulation with l-dopa/l-carbidopa by simultaneous administration of propranolol (author"s transl)]. Levodopa 48-54 growth hormone 1 Homo sapiens 16-30 520175-5 1979 Some of the children who previously had failed to have a satisfactory rise in growth-hormone level after L-dopa and L-carbidopa showed satisfactory stimulation when propranolol was added. Levodopa 105-111 growth hormone 1 Homo sapiens 78-92 119594-5 1979 In five out of six cirrhotic patients oral administration of L-Dopa was followed by the usual rise in plasma GH. Levodopa 61-67 growth hormone 1 Homo sapiens 109-111 485891-0 1979 Administration of human somatotropin in levodopa-treated patients with Parkinsonism. Levodopa 40-48 growth hormone 1 Homo sapiens 24-36 520077-1 1979 A comparison between insulin-induced hypoglycaemia and levodopa as stimuli for growth hormone secretion in patients with hypothalamic-pituitary insufficiency and in normal subjects. Levodopa 55-63 growth hormone 1 Homo sapiens 79-93 451694-0 1979 Combined oral L-dopa and propranolol for growth hormone provocation. Levodopa 14-20 growth hormone 1 Homo sapiens 41-55 499111-0 1979 [Effect of long-term fasting on the blood serum insulin and growth hormone levels after loading tests with glucose, levodopa and exertion in obese patients with mormal and abnormal carbohydrate tolerance]. Levodopa 116-124 growth hormone 1 Homo sapiens 60-74 480794-0 1979 [Stimulation of growth hormone (STH) in the outpatient clinic using L-Dopa plus carbidopa and physical loading]. Levodopa 68-74 growth hormone 1 Homo sapiens 16-30 162179-3 1979 Data on prolactin and growth hormone response to levodopa in bipolar and unipolar illness presented. Levodopa 49-57 growth hormone 1 Homo sapiens 22-36 467382-0 1979 [Growth hormone secretion after oral administration of L-dopa in primary hypothyroidism]. Levodopa 55-61 growth hormone 1 Homo sapiens 1-15 581754-7 1979 We calculated the responsiveness of the plasma GH level as follows: GH responsiveness (%) = (mean plasma GH level after the administration of CB-154 or L-DOPA)/ (basal GH level) x 100. Levodopa 152-158 growth hormone 1 Homo sapiens 47-49 571063-1 1979 In 19 patients with Parkinson disease, we studied the relationship of the therapeutic effect of levodopa, or dyskinesia, to the plasma content of DOPA and growth hormone (GH). Levodopa 96-104 growth hormone 1 Homo sapiens 155-169 571063-1 1979 In 19 patients with Parkinson disease, we studied the relationship of the therapeutic effect of levodopa, or dyskinesia, to the plasma content of DOPA and growth hormone (GH). Levodopa 96-104 growth hormone 1 Homo sapiens 171-173 517160-0 1979 Secretion of growth hormone after L-dopa stimulation in patients with renal failure treated with dialyses. Levodopa 34-40 growth hormone 1 Homo sapiens 13-27 155781-4 1979 Oral administration of Bro (2.5 mg po) or L-dopa (500 mg), or subcutaneous administration of Apo (1.0 mg) resulted in a significantly greater and more prompt (Bro, L-dopa) increase in plasma GH in patients than in controls. Levodopa 42-48 growth hormone 1 Homo sapiens 191-193 263317-0 1978 Carbidopa inhibits the growth hormone- and prolactin-suppressive effect of L-dopa in acromegalic patients. Levodopa 75-81 growth hormone 1 Homo sapiens 23-37 756876-0 1978 Effect of hyperglycemia on the growth hormone response to L-dopa in diabetic subjects. Levodopa 58-64 growth hormone 1 Homo sapiens 31-45 626554-3 1978 In addition we demonstrated alterations in growth hormone regulation, characterized by (1) the lack of suppression of growth hormone by orally induced hyperglycemia and paradoxical increase in serum levels of growth hormone after the administration of intravenous glucose or glucagon; (2) lack of release of growth hormone with induced hypoglycemia and an exaggerated response to levodopa administration. Levodopa 380-388 growth hormone 1 Homo sapiens 43-57 749825-0 1978 Impaired responses of growth hormone and blood eosinophils to L-dopa in atopy [proceedings]. Levodopa 62-68 growth hormone 1 Homo sapiens 22-36 731719-5 1978 The mean serum GH concentration was 2.2 ng/ml, which suppressed to 0.6 ng/ml during the GTT; increased to 24 ng/ml during hypoglycemia; and increased to 10.3 ng/ml after L-dopa ingestion. Levodopa 170-176 growth hormone 1 Homo sapiens 15-17 640244-6 1978 The increase of plasma GH after L-dopa in both healthy persons and diabetics and the inhibition of this response by glucose in healthy subjects was reconfirmed. Levodopa 32-38 growth hormone 1 Homo sapiens 23-25 640244-7 1978 Furthermore, the same effect of exogenous glucose on the L-dopa induced GH release was observed in diabetics. Levodopa 57-63 growth hormone 1 Homo sapiens 72-74 566402-0 1978 [Changes induced with L-dopa in the serum levels of prolactin and somatotropin in the diagnosis of amenorrhea-galactorrhea]. Levodopa 22-28 growth hormone 1 Homo sapiens 66-78 628352-0 1978 Growth hormone response to propranolol and L--dopa in obese subjects. Levodopa 43-50 growth hormone 1 Homo sapiens 0-14 628352-1 1978 Oral administration of propranolol and L-dopa produced a marked increase in plasma growth hormone values in 12 obese subjects who had failed to respond to L-dopa alone. Levodopa 39-45 growth hormone 1 Homo sapiens 83-97 628352-1 1978 Oral administration of propranolol and L-dopa produced a marked increase in plasma growth hormone values in 12 obese subjects who had failed to respond to L-dopa alone. Levodopa 155-161 growth hormone 1 Homo sapiens 83-97 339647-0 1977 Impaired responses of growth hormone and blood eosinophils to L-dopa in atopy. Levodopa 62-68 growth hormone 1 Homo sapiens 22-36 339647-4 1977 The mean rise in GH 30 and 60 min after L-dopa was significantly lower in atopic patients as compared with controls. Levodopa 40-46 growth hormone 1 Homo sapiens 17-19 598566-0 1977 Inhibition of L-dopa induced growth hormone release in normal and diabetic subjects by glucose administration. Levodopa 14-20 growth hormone 1 Homo sapiens 29-43 598566-1 1977 Administration of L-dopa 1 g induced an increase of plasma growth hormone (GH) levels in seven of ten healthy volunteers and in six of ten hyperglycemic insulin-dependent diabetic subjects; the maximal GH response was higher in normal subjects. Levodopa 18-24 growth hormone 1 Homo sapiens 59-73 598566-1 1977 Administration of L-dopa 1 g induced an increase of plasma growth hormone (GH) levels in seven of ten healthy volunteers and in six of ten hyperglycemic insulin-dependent diabetic subjects; the maximal GH response was higher in normal subjects. Levodopa 18-24 growth hormone 1 Homo sapiens 75-77 598566-1 1977 Administration of L-dopa 1 g induced an increase of plasma growth hormone (GH) levels in seven of ten healthy volunteers and in six of ten hyperglycemic insulin-dependent diabetic subjects; the maximal GH response was higher in normal subjects. Levodopa 18-24 growth hormone 1 Homo sapiens 202-204 598566-2 1977 Addition of 100 g glucose orally to the L-dopa completely abolished the GH response of both groups. Levodopa 40-46 growth hormone 1 Homo sapiens 72-74 598566-3 1977 The difference between the effect of endogenous hyperglycemia and the effect of a sudden increase of blood sugar after glucose administration on L-dopa induced GH release in diabetic subjects may be explain by the resetting of the hypothalamic control for pituitary GH release to higher levels of blood glucose. Levodopa 145-151 growth hormone 1 Homo sapiens 160-162 598566-3 1977 The difference between the effect of endogenous hyperglycemia and the effect of a sudden increase of blood sugar after glucose administration on L-dopa induced GH release in diabetic subjects may be explain by the resetting of the hypothalamic control for pituitary GH release to higher levels of blood glucose. Levodopa 145-151 growth hormone 1 Homo sapiens 266-268 591612-1 1977 In 6 normal subjects, L-dopa (500 mg PO) and apomorphine (0.6 mg sc) increased circulating growth hormone and suppressed prolactin levels in a parallel and quantitatively similar fashion, but only L-dopa induced a rise in plasma glucagon, glucose, and insulin levels. Levodopa 22-28 growth hormone 1 Homo sapiens 91-105 910982-3 1977 In another group of subjects with depression, the stimulation of growth hormone secretion by L-dopa was unaffected by amitriptyline therapy. Levodopa 93-99 growth hormone 1 Homo sapiens 65-79 155781-4 1979 Oral administration of Bro (2.5 mg po) or L-dopa (500 mg), or subcutaneous administration of Apo (1.0 mg) resulted in a significantly greater and more prompt (Bro, L-dopa) increase in plasma GH in patients than in controls. Levodopa 164-170 growth hormone 1 Homo sapiens 191-193 914981-3 1977 Melatonin appeared to depress the level of luteinizing hormone (LH) in serum and may have inhibited in some patients the release of growth hormone from the pituitary gland after stimulation by stress or L-dopa. Levodopa 203-209 growth hormone 1 Homo sapiens 132-146 838854-0 1977 Transient appearance of a provocative growth hormone response to L-dopa following incomplete adenomectomy in an acromegalic patient. Levodopa 65-71 growth hormone 1 Homo sapiens 38-52 20170-1 1977 500 mg of levodopa was administered orally to 8 normal subjects and induced an increase of growth hormone (GH) and a decrease of prolactin (PRL) secretion. Levodopa 10-18 growth hormone 1 Homo sapiens 91-105 20170-1 1977 500 mg of levodopa was administered orally to 8 normal subjects and induced an increase of growth hormone (GH) and a decrease of prolactin (PRL) secretion. Levodopa 10-18 growth hormone 1 Homo sapiens 107-109 20170-2 1977 The levodopa-induced GH release was inhibited by an intravenous infusion of pyridoxine; on the contrary, the PRL response to levodopa was enhanced by pyridoxine infusion. Levodopa 4-12 growth hormone 1 Homo sapiens 21-23 20170-3 1977 This dissociation of GH and PRL responses to levodopa during pyridoxine infusion appears to be mediated by peripheral acceleration of the conversion of levodopa to dopamine. Levodopa 45-53 growth hormone 1 Homo sapiens 21-23 900875-2 1977 The present study aimed at testing the hypothesis that l-dopa could obtain a better growth hormone (G.H.) Levodopa 55-61 growth hormone 1 Homo sapiens 84-98 404727-0 1977 Abnormal growth hormone responses to L-dopa and thyrotropin-releasing hormone in patients with acromegaly. Levodopa 37-43 growth hormone 1 Homo sapiens 9-23 404727-1 1977 Changes in growth hormone (gh) release in response to L-dopa, TRH, arginine and LH-RH were studied in 15 patients with acromegaly to investigate the mechanism of so-called "paradoxical decrease" of GH secretion often observed in acromegalics after the administration of L-dopa. Levodopa 54-60 growth hormone 1 Homo sapiens 11-25 404727-1 1977 Changes in growth hormone (gh) release in response to L-dopa, TRH, arginine and LH-RH were studied in 15 patients with acromegaly to investigate the mechanism of so-called "paradoxical decrease" of GH secretion often observed in acromegalics after the administration of L-dopa. Levodopa 54-60 growth hormone 1 Homo sapiens 27-29 835536-0 1977 Sequential use of insulin and levodopa to provoke pituitary secretion of growth hormone. Levodopa 30-38 growth hormone 1 Homo sapiens 73-87 908155-0 1977 Effect of pimozide on levodopa-induced growth hormone release in man. Levodopa 22-30 growth hormone 1 Homo sapiens 39-53 875737-2 1977 The oral administration of cyproheptadine (12 mg daily) reduced GH responses to both L-dopa and glucagon; similarly, the mean GH response to oral glucose administration was significantly reduced after cyproheptadine administration. Levodopa 85-91 growth hormone 1 Homo sapiens 64-66 901702-7 1977 5 Levodopa (250 mg) with (-)-alpha-methyldopa hydrazine 25 mg (Sinemet) by mouth, caused a rise in plasma growth hormone concentration in most normal subjects. Levodopa 2-10 growth hormone 1 Homo sapiens 106-120 320826-0 1977 Secretion of human growth hormone and insulin in levodopa test during carbamazepine therapy. Levodopa 49-57 growth hormone 1 Homo sapiens 19-33 320826-2 1977 Serum growth hormone rose significantly from 1.3 +/- 0.3 ng/ml to 16.3 +/- 3.4 ng/ml in 60 minutes after levodopa administration (1000 mg orally) before carbamazepine, and almost similarly from 2.3 +/- 0.5 ng/ml to 15.1 +/- 4.0 ng/ml after carbamazepine during the test. Levodopa 105-113 growth hormone 1 Homo sapiens 6-20 864480-0 1977 Plasma DOPA levels and growth hormone response to levodopa in parkinsomism. Levodopa 50-58 growth hormone 1 Homo sapiens 23-37 864480-1 1977 It has been suggested that the therapeutic response to levodopa in patients with Parkinson"s disease may be related to changes in plasma growth hormone concentration. Levodopa 55-63 growth hormone 1 Homo sapiens 137-151 864480-3 1977 Levodopa caused an increase in plasma growth hormone concentration in 30 subjects. Levodopa 0-8 growth hormone 1 Homo sapiens 38-52 864480-5 1977 The growth hormone response to levodopa is normal in patients with Parkinson"s disease and not altered by long-term levodopa treatment. Levodopa 31-39 growth hormone 1 Homo sapiens 4-18 831384-0 1977 The effect of L-dopa with and without decarboxylase inhibitor on growth hormone secretion in children with short stature. Levodopa 14-20 growth hormone 1 Homo sapiens 65-79 833257-0 1977 L-Dopa stimulated growth hormone release in the blind. Levodopa 0-6 growth hormone 1 Homo sapiens 18-32 833257-1 1977 Following L-Dopa administration (single oral dose of 500 mg), plasma Growth hormone (GH) levels significantly rose in 7 out of 8 normal subjects (aged between 64-83) and in 4 out of 8 blind subjects (aged between 60-88). Levodopa 10-16 growth hormone 1 Homo sapiens 69-83 833257-1 1977 Following L-Dopa administration (single oral dose of 500 mg), plasma Growth hormone (GH) levels significantly rose in 7 out of 8 normal subjects (aged between 64-83) and in 4 out of 8 blind subjects (aged between 60-88). Levodopa 10-16 growth hormone 1 Homo sapiens 85-87 829393-0 1976 Growth hormone response to L-dopa in diabetes mellitus. Levodopa 27-33 growth hormone 1 Homo sapiens 0-14 1036999-7 1976 Levodopa 2 g had a greater therapeutic effect and caused a greater rise in plasma growth hormone concentration than bromocriptine 100 mg. Levodopa caused emesis more commonly and hallucinations less commonly than bromocriptine. Levodopa 0-8 growth hormone 1 Homo sapiens 82-96 1036999-7 1976 Levodopa 2 g had a greater therapeutic effect and caused a greater rise in plasma growth hormone concentration than bromocriptine 100 mg. Levodopa caused emesis more commonly and hallucinations less commonly than bromocriptine. Levodopa 138-146 growth hormone 1 Homo sapiens 82-96 970425-0 1976 Levodopa-stimulated growth hormone secretion and diabetic retinopathy. Levodopa 0-8 growth hormone 1 Homo sapiens 20-34 970425-3 1976 Basal and levodopa-stimulated levels of growth hormone were determined for each group. Levodopa 10-18 growth hormone 1 Homo sapiens 40-54 795689-4 1976 Parenteral administration of synthetic SRIF inhibits the release of growth hormone, basal and stimulated by muscular exercise, arginine, L-DOPA, insulin-induced hypoglycemia, and sleeping. Levodopa 137-143 growth hormone 1 Homo sapiens 68-82 991841-0 1976 [Growth hormone concentration during sleep following L-dopa administration]. Levodopa 53-59 growth hormone 1 Homo sapiens 1-15 824407-4 1976 It was found that after levodopa administration the plasma free fatty acids, glucose, growth hormone and cortisol were significantly higher in the Parkinsonian group than in the young control group and only slightly higher than in the aged control group. Levodopa 24-32 growth hormone 1 Homo sapiens 86-100 961756-1 1976 The time course of simultaneous changes in prolactin (PRL) and growth hormone secretion in response to a single dose of L-dopa and chlorpromazine was determined in normal women. Levodopa 120-126 growth hormone 1 Homo sapiens 63-77 961756-2 1976 L-Dopa induced greater, but shorter (30 minutes), growth hormone release than concomitant suppression of PRL secretion. Levodopa 0-6 growth hormone 1 Homo sapiens 50-64 1269163-0 1976 A comparison of the effect of levodopa and somatostatin on the plasma levels of growth hormone, insulin, glucagon and prolactin in acromegaly. Levodopa 30-38 growth hormone 1 Homo sapiens 80-94 932184-0 1976 Growth hormone refractory interval to levodopa stimulation. Levodopa 38-46 growth hormone 1 Homo sapiens 0-14 1012176-0 1976 [Test with levodopa in the evaluation of somatotropin secretion]. Levodopa 11-19 growth hormone 1 Homo sapiens 41-53 1261961-0 1976 Effect of metergoline, a specific serotonin antagonist, on human growth hormone response to arginine and L-dopa. Levodopa 105-111 growth hormone 1 Homo sapiens 65-79 994683-0 1976 [Stimulation of growth hormone by L-dopa in mental anorexia]. Levodopa 34-40 growth hormone 1 Homo sapiens 16-30 971548-1 1976 In ten normal subjects and in twenty acromegalic patients plasma levels of growth hormone were studied after administration of L-dopa and a dopamine infusion. Levodopa 127-133 growth hormone 1 Homo sapiens 75-89 1252146-1 1976 The flat serum growth hormone (GH) patterns of untreated parkinsonian patients develop diurnal rises during treatment with levodopa. Levodopa 123-131 growth hormone 1 Homo sapiens 15-29 1252146-1 1976 The flat serum growth hormone (GH) patterns of untreated parkinsonian patients develop diurnal rises during treatment with levodopa. Levodopa 123-131 growth hormone 1 Homo sapiens 31-33 985031-0 1976 [Attempt at potentiation of the action of L-dopa on the secretion of growth hormone by benserazide, disulfiram and propranolol]. Levodopa 42-48 growth hormone 1 Homo sapiens 69-83 821792-1 1975 Growth hormone (GH) responses to L-dopa, 2-Br-alpha-ergocryptine (CB-154), thyrotropine-releasing hormone (TRH), luteinizing hormone-releasing hormone (LH-RH), glucagon and glucose were investigated in six patients with active acromegaly. Levodopa 33-39 growth hormone 1 Homo sapiens 0-14 1185416-5 1975 Growth hormone responses to arginine, insulin, sleep, L-dopa, and glucagon were uniformly less than 2.5 ng/ml. Levodopa 54-60 growth hormone 1 Homo sapiens 0-14 1227747-0 1975 [Effect of carbidopa and L-dopa combination on the secretion of growth hormone in normal subjects and in patients with Parkinsonism]. Levodopa 25-31 growth hormone 1 Homo sapiens 64-78 1159580-0 1975 Evaluation of growth hormone release in children using arginine and L-dopa in combination. Levodopa 68-74 growth hormone 1 Homo sapiens 14-28 239963-0 1975 Suppression by thyrotropin-releasing hormone (TRH) of human growth hormone release induced by L-dopa. Levodopa 94-100 growth hormone 1 Homo sapiens 60-74 239963-1 1975 Oral administration of L-dopa (600 mg) significantly raised plasma human growth hormone (hGH) in 6 of 7 normal subjects examined. Levodopa 23-29 growth hormone 1 Homo sapiens 73-87 1201741-0 1975 Suppressive effect of cyproheptadine on L-DOPA-induced growth hormone release in man. Levodopa 40-46 growth hormone 1 Homo sapiens 55-69 1149303-0 1975 Comparison of the effect of apomorphine and L-DOPA on serum growth hormone levels in normal men. Levodopa 44-50 growth hormone 1 Homo sapiens 60-74 1158662-0 1975 Under-responsiveness of growth hormone secretion after L-dopa and deep sleep stimulation in obese subjects. Levodopa 55-61 growth hormone 1 Homo sapiens 24-38 1158029-0 1975 Effect of glucose on the growth hormone response to L-dopa in normal and diabetic subjects. Levodopa 52-58 growth hormone 1 Homo sapiens 25-39 1158029-1 1975 The effect of hyperglycemia on the growth hormone response to oral L-dopa (500 mg.) was assessed in eight normal and eight insulin-dependent diabetic subjects. Levodopa 67-73 growth hormone 1 Homo sapiens 35-49 1158029-8 1975 oral glucose with the L-dopa, or thirty minutes thereafter, totally suppressed the growth hormone response in all eight and six of the subjects, respectively. Levodopa 22-28 growth hormone 1 Homo sapiens 83-97 1153917-0 1975 The effect of somatostatin on the rise of growth hormone and glucagon secretion induced by arginine and L-dopa in diabetic patients. Levodopa 104-110 growth hormone 1 Homo sapiens 42-56 1153917-2 1975 The plasma growth hormone response to arginine and L-dopa was completely inhibited by somatostatin. Levodopa 51-57 growth hormone 1 Homo sapiens 11-25 1134455-0 1975 [Effects of oral administration of L-dopa on the secretion of plasma growth hormone in subjects of pediatric age]. Levodopa 35-41 growth hormone 1 Homo sapiens 69-83 1119901-0 1975 Human growth hormone response to levodopa. Levodopa 33-41 growth hormone 1 Homo sapiens 6-20 1119901-2 1975 After ingestion of 500 mg of levodopa, postmenopausal women had significantly diminished human growth hormone (HGH) responses (mean, 4.6 ng/ml), as compared with those of age-matched men (mean, 9.1 ng/ml; P smaller than .05). Levodopa 29-37 growth hormone 1 Homo sapiens 95-109 1117978-0 1975 Inhibition of L-dopa-induced growth hormone stimulation by pyridoxine and chlorpromazine. Levodopa 14-20 growth hormone 1 Homo sapiens 29-43 1117978-1 1975 One gram of L-dopa was administered orally to 12 male control subjects and induced an increase of growth hormone (GH) secretion. Levodopa 12-18 growth hormone 1 Homo sapiens 98-112 1117978-1 1975 One gram of L-dopa was administered orally to 12 male control subjects and induced an increase of growth hormone (GH) secretion. Levodopa 12-18 growth hormone 1 Homo sapiens 114-116 1117978-2 1975 The L-dopa-induced GH response was inhibited by an intravenous infusion of pyridoxine, but pyridoxine did not inhibit the GH response to hypoglycemia. Levodopa 4-10 growth hormone 1 Homo sapiens 19-21 1117978-3 1975 Chlorpromazine also inhibited L-dopa-induced GH stimulation. Levodopa 30-36 growth hormone 1 Homo sapiens 45-47 1171032-0 1975 [A low response of pituitary growth hormone secretion in the patient with diabetes mellitus after intravenous administration of L-dopa (author"s transl)]. Levodopa 128-134 growth hormone 1 Homo sapiens 29-43 1171032-1 1975 Recently, L-dopa has been known as one of drugs to stimulate the secretion of growth hormone from the pituitary gland through dopamine, which is a metabolic of L-dopa, without any changes of serum insulin levels, blood sugar values, fatty acids and amino acids concentrations in the serum of human being. Levodopa 10-16 growth hormone 1 Homo sapiens 78-92 1171032-1 1975 Recently, L-dopa has been known as one of drugs to stimulate the secretion of growth hormone from the pituitary gland through dopamine, which is a metabolic of L-dopa, without any changes of serum insulin levels, blood sugar values, fatty acids and amino acids concentrations in the serum of human being. Levodopa 160-166 growth hormone 1 Homo sapiens 78-92 1171032-2 1975 The present study was thus designed to assess the effect of L-dopa on the pituitary gland to secrete the growth hormone in the normal subject and the study was further extended to compare the response of the pituitary secretion of the growth hormone following the administration of L-dopa between in the patient with diabetes mellitus and in the normal subject. Levodopa 60-66 growth hormone 1 Homo sapiens 105-119 1171032-2 1975 The present study was thus designed to assess the effect of L-dopa on the pituitary gland to secrete the growth hormone in the normal subject and the study was further extended to compare the response of the pituitary secretion of the growth hormone following the administration of L-dopa between in the patient with diabetes mellitus and in the normal subject. Levodopa 282-288 growth hormone 1 Homo sapiens 235-249 1171032-6 1975 In the patients with diabetes mellitus, on the other hand, maximum value of serum concentration of the growth hormone was only approximately 5 ng/ml of serum obtained between 45 and 75 min after the administration of L-dopa. Levodopa 217-223 growth hormone 1 Homo sapiens 103-117 1117978-5 1975 The mechanism of the suppressed L-dopa-induced GH response by pyridoxine appears to be mediated by peripheral accleration of the conversion of L-dopa to dopamine, while that of chlorpromazine appears to be mediated through hypothalamic centers. Levodopa 32-38 growth hormone 1 Homo sapiens 47-49 1117978-5 1975 The mechanism of the suppressed L-dopa-induced GH response by pyridoxine appears to be mediated by peripheral accleration of the conversion of L-dopa to dopamine, while that of chlorpromazine appears to be mediated through hypothalamic centers. Levodopa 143-149 growth hormone 1 Homo sapiens 47-49 1117978-6 1975 Pyridoxine and chlorpromazine should be added to the list of other factors affecting the response to L-dopa-induced GH stimulation Levodopa 101-107 growth hormone 1 Homo sapiens 116-118 4698567-0 1973 Potentiation of levodopa stimulation of human growth hormone by systemic decarboxylase inhibition. Levodopa 16-24 growth hormone 1 Homo sapiens 46-60 54462-0 1975 [Method of determination of somatotropin level in blood plasma with L-dopa loading in patients with diabetes mellitus complicated by microangiopathies]. Levodopa 68-74 growth hormone 1 Homo sapiens 28-40 4428963-0 1974 The effect of L-dopa on the blood concentrations of growth hormone, thyrotrophin, gonadotrophins, cortisol and glucose in children with short stature. Levodopa 14-20 growth hormone 1 Homo sapiens 52-66 4133478-0 1974 Letter: Enhancement of levodopa-induced growth-hormone stimulation by propranolol. Levodopa 23-31 growth hormone 1 Homo sapiens 40-54 4454413-0 1974 [Stimulation of growth hormone secretion by the anterior pituitary gland using L-DOPA compared to growth hormone secretion following argine, insulin and sleep]. Levodopa 79-85 growth hormone 1 Homo sapiens 16-30 4200807-0 1973 The levodopa test of growth hormone reserve in children. Levodopa 4-12 growth hormone 1 Homo sapiens 21-35 4682676-0 1973 Defective release of growth hormone in parkinsonism improved by levodopa. Levodopa 64-72 growth hormone 1 Homo sapiens 21-35 4139577-0 1974 Letter: Enhancement of levodopa-induced growth-hormone stimulation by practolol. Levodopa 23-31 growth hormone 1 Homo sapiens 40-54 4439528-0 1974 [Stimulation of growth hormone (HGH) with L-dopa]. Levodopa 42-48 growth hormone 1 Homo sapiens 16-30 4813957-0 1974 Plasma growth hormone response to L-dopa in obese subjects. Levodopa 34-40 growth hormone 1 Homo sapiens 7-21 4356808-0 1973 Growth hormone and prolactin in unipolar and bipolar depressed patients: responses to hypoglycemia and L-dopa. Levodopa 103-109 growth hormone 1 Homo sapiens 0-14 4767002-0 1973 Amantadine enhancement of L-DOPA induced growth hormone stimulation. Levodopa 26-32 growth hormone 1 Homo sapiens 41-55 4709329-0 1973 Glucose-suppressible growth hormone release after L-dopa administration to normal subjects. Levodopa 50-56 growth hormone 1 Homo sapiens 21-35 4770263-0 1973 Effect of L-dopa on the secretion of plasma growth hormone in children and adolescents. Levodopa 10-16 growth hormone 1 Homo sapiens 44-58 4706921-0 1973 Effect of intravenous infusion of L-DOPA on plasma growth hormone levels in man. Levodopa 34-40 growth hormone 1 Homo sapiens 51-65 4722572-0 1973 Plasma growth hormone and insulin response to levodopa and amantadine. Levodopa 46-54 growth hormone 1 Homo sapiens 7-21 4275115-0 1973 Biogenic amines in the hypothalamus: effect of L-DOPA on human growth hormone levels in patients with Huntington"s chorea. Levodopa 47-53 growth hormone 1 Homo sapiens 63-77 4640070-0 1972 Growth hormone responses to L-dopa in depressed patients. Levodopa 28-34 growth hormone 1 Homo sapiens 0-14 4640070-1 1972 Plasma human growth hormone responses to oral administration of 500 milligrams of L-dopa were analyzed in three groups of subjects: normals, age 20 to 32; normals, age 48 to 68; and unipolar depressed patients, age 45 to 68. Levodopa 82-88 growth hormone 1 Homo sapiens 13-27 4668972-0 1972 Release of human growth hormone, follicle stimulating hormone, and luteinizing hormone in response to L-dihydroxy-phenylalanine (L-dopa) in normal man. Levodopa 129-135 growth hormone 1 Homo sapiens 17-31 5074361-0 1972 Effect of L-dihydroxyphenylalanine upon serum growth hormone concentrations in children and adolescents. Levodopa 10-34 growth hormone 1 Homo sapiens 46-60 5071365-0 1972 Effect of L-dopa administration on growth hormone secretion in normal subjects and Parkinsonian patients. Levodopa 10-16 growth hormone 1 Homo sapiens 35-49 4673195-0 1972 [Fluctuations of plasma concentration of growth hormone (GH) and cortisol in man during administration of L-DOPA. Levodopa 106-112 growth hormone 1 Homo sapiens 41-55 4673195-0 1972 [Fluctuations of plasma concentration of growth hormone (GH) and cortisol in man during administration of L-DOPA. Levodopa 106-112 growth hormone 1 Homo sapiens 57-59 4554974-0 1972 Phentolamine inhibition of human growth hormone secretion induced by L-DOPA. Levodopa 69-75 growth hormone 1 Homo sapiens 33-47 4935302-11 1971 * Levodopa as a possible specific stimulus to growth hormone release has just been reported and the implications of this finding for the child of short stature cannot yet be assessed. Levodopa 2-10 growth hormone 1 Homo sapiens 46-60 5481776-0 1970 Stimulation of human-growth-hormone secretion by L-dopa. Levodopa 49-55 growth hormone 1 Homo sapiens 21-35 4324569-0 1970 Corticosteroid and growth hormone secretion in patients treated with L-dopa. Levodopa 69-75 growth hormone 1 Homo sapiens 19-33 29341046-1 2018 The purpose of the study was to evaluate the relationship between arginine-levodopa-induced growth hormone (GH) secretion and nonalcoholic fatty liver disease (NAFLD) in obese children. Levodopa 75-83 growth hormone 1 Homo sapiens 92-106